Please select the option that best describes you:
Do you recommend lenalidomide for high risk smoldering multiple myeloma?
Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM patients on lenalidomide?
Would you add dexamethasone to the regimen, and if so in what circumstances?
Lonial et al. J Clin Oncol. 2019 Oct 25:JCO1901740. doi: 10.1200/JCO.19.01740.
Mateos et al. N Engl J Med 2013; 369:438-447. doi: 10.1056/NEJMoa1300439.
Answer from: Medical Oncologist at Academic Institution
If you want to push the can down the road that is a good approach. High risk SMM is more like early stage myeloma. Treating them with single agent does not make sense as we know that combination therapy and total therapy approach is superior. The ECOG study was perfect 15 years ago but not today.&nb...
Sign in or Register to read more